- Home
- EVOK vs PPBT Comparison
EVOK vs PPBT Comparison
Compare EVOK & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- PPBT
- Stock Information
- Founded
- EVOK 2007
- PPBT 2010
- Country
- EVOK United States
- PPBT Israel
- Employees
- EVOK 3
- PPBT N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- PPBT Health Care
- Exchange
- EVOK Nasdaq
- PPBT Nasdaq
- Market Cap
- EVOK 7.6M
- PPBT 5.5M
- IPO Year
- EVOK 2013
- PPBT N/A
- Fundamental
- Price
- EVOK $4.90
- PPBT $1.09
- Analyst Decision
- EVOK
- PPBT Strong Buy
- Analyst Count
- EVOK 0
- PPBT 1
- Target Price
- EVOK N/A
- PPBT $33.00
- AVG Volume (30 Days)
- EVOK 27.4K
- PPBT 234.4K
- Earning Date
- EVOK 11-07-2025
- PPBT 11-14-2025
- Dividend Yield
- EVOK N/A
- PPBT N/A
- EPS Growth
- EVOK N/A
- PPBT N/A
- EPS
- EVOK N/A
- PPBT N/A
- Revenue
- EVOK $12,794,859.00
- PPBT N/A
- Revenue This Year
- EVOK $57.38
- PPBT N/A
- Revenue Next Year
- EVOK $59.57
- PPBT N/A
- P/E Ratio
- EVOK N/A
- PPBT N/A
- Revenue Growth
- EVOK 70.02
- PPBT N/A
- 52 Week Low
- EVOK $1.94
- PPBT $0.53
- 52 Week High
- EVOK $12.32
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- EVOK 52.02
- PPBT 72.05
- Support Level
- EVOK $4.53
- PPBT $0.57
- Resistance Level
- EVOK $4.69
- PPBT $0.61
- Average True Range (ATR)
- EVOK 0.27
- PPBT 0.04
- MACD
- EVOK 0.06
- PPBT 0.07
- Stochastic Oscillator
- EVOK 61.43
- PPBT 81.45
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.